Login to Your Account



Merck advances Oncothyreon’s cancer vaccine in NSCLC

By Michael Fitzhugh
Staff Writer

Monday, April 7, 2014

Oncothyreon Inc. said that Merck KGaA has started a phase III trial of its out-licensed cancer vaccine tecemotide in patients with unresectable, locally advanced stage III non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription